Carfilzomib @ ASH 2019
Neue Studiendaten zur Behandlung des Multiplen Myeloms mit Carfilzomib.
Neue Studiendaten zur Behandlung des Multiplen Myeloms mit Carfilzomib.
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties